NANOBIOTIX to Participate in Multiple Investor Conferences in November
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, announces participation in three major healthcare conferences in November 2024. The company will engage in fireside chats at Guggenheim's Inaugural Healthcare Innovation Conference (Nov 11, Boston), the Stifel Healthcare Conference (Nov 18, New York), and the Jefferies London Healthcare Conference (Nov 20, London). Company executives Laurent Levy (CEO) and Bart van Rhijn (CFO) will present at these events. All sessions will be webcast live and available for replay on the company's investor relations website.
Nanobiotix (NASDAQ: NBTX), un'azienda biotecnologica in fase clinica avanzata focalizzata sui trattamenti anticancro basati su nanoparticelle, annuncia la sua partecipazione a tre importanti conferenze sanitarie nel novembre 2024. L'azienda sarà presente a discussioni informali alla Inaugural Healthcare Innovation Conference di Guggenheim (11 novembre, Boston), alla Stifel Healthcare Conference (18 novembre, New York) e alla Jefferies London Healthcare Conference (20 novembre, Londra). I dirigenti dell'azienda Laurent Levy (CEO) e Bart van Rhijn (CFO) presenteranno in questi eventi. Tutte le sessioni saranno trasmesse in diretta e disponibili per la visione on-demand sul sito web delle relazioni con gli investitori dell'azienda.
Nanobiotix (NASDAQ: NBTX), una empresa biotecnológica en fase clínica avanzada centrada en tratamientos contra el cáncer basados en nanopartículas, anuncia su participación en tres importantes conferencias de salud en noviembre de 2024. La compañía participará en charlas informales en la Inaugural Healthcare Innovation Conference de Guggenheim (11 de noviembre, Boston), la Stifel Healthcare Conference (18 de noviembre, Nueva York) y la Jefferies London Healthcare Conference (20 de noviembre, Londres). Los ejecutivos de la empresa Laurent Levy (CEO) y Bart van Rhijn (CFO) presentarán en estos eventos. Todas las sesiones se transmitirán en vivo y estarán disponibles para reproducción en el sitio web de relaciones con los inversores de la empresa.
Nanobiotix (NASDAQ: NBTX)는 나노 입자 기반 암 치료에 집중하는 임상 후기 단계의 생명공학 회사로, 2024년 11월에 열리는 세 가지 주요 의료 컨퍼런스에 참여한다고 발표했습니다. 이 회사는 구겐하임의 제1회 의료 혁신 컨퍼런스 (11월 11일, 보스턴), 스티펠 의료 컨퍼런스 (11월 18일, 뉴욕) 및 제프리스 런던 의료 컨퍼런스 (11월 20일, 런던)에서 캐주얼 대담에 참가합니다. 회사의 경영진인 로랑 레비(CEO)와 바르트 판 라이힌(CFO)이 이러한 행사에서 발표할 예정입니다. 모든 세션은 생중계되며, 회사의 투자자 관계 웹사이트에서 다시 볼 수 있습니다.
Nanobiotix (NASDAQ: NBTX), une entreprise de biotechnologie en phase clinique avancée spécialisée dans les traitements anticancéreux à base de nanoparticules, annonce sa participation à trois grandes conférences de santé en novembre 2024. L'entreprise participera à des discussions informelles lors de la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim (11 novembre, Boston), de la Conférence Stifel sur la Santé (18 novembre, New York) et de la Conférence Jefferies de Londres sur la Santé (20 novembre, Londres). Les dirigeants de l'entreprise, Laurent Levy (CEO) et Bart van Rhijn (CFO), présenteront lors de ces événements. Toutes les sessions seront diffusées en direct et disponibles en replay sur le site web des relations avec les investisseurs de l'entreprise.
Nanobiotix (NASDAQ: NBTX), ein biotechnologisches Unternehmen in der späten klinischen Phase, das sich auf nanopartikelbasierte Krebsbehandlungen spezialisiert hat, kündigt seine Teilnahme an drei bedeutenden Gesundheitskonferenzen im November 2024 an. Das Unternehmen wird an informellen Gesprächen auf der Ersten Gesundheitsinnovationskonferenz von Guggenheim (11. November, Boston), der Stifel Gesundheitskonferenz (18. November, New York) und der Jefferies London Gesundheitskonferenz (20. November, London) teilnehmen. Die Unternehmensführung, bestehend aus Laurent Levy (CEO) und Bart van Rhijn (CFO), wird auf diesen Veranstaltungen präsentieren. Alle Sitzungen werden live übertragen und können auf der Webseite der Investorenbeziehungen des Unternehmens wiederholt werden.
- None.
- None.
~ Guggenheim’s Inaugural Healthcare Innovation Conference, Nov 11-13 ~
~ Stifel Healthcare Conference, Nov 18-19 ~
~ Jefferies London Healthcare Conference, Nov 19-21 ~
PARIS and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences:
Guggenheim’s Inaugural Healthcare Innovation Conference
Date: Monday, November 11, 2024
Time: 4pm ET / 10pm CET
Location: Boston, MA
Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here
Stifel Healthcare Conference
Date: Monday, November 18, 2024
Time: 4:45pm ET / 10:45pm CET
Location: New York, NY
Presenter: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here
Jefferies London Healthcare Conference
Date: Wednesday, November 20, 2024
Time: 1pm GMT / 8am ET / 2pm CET
Location: London, UK
Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here
The fireside chats will be webcast live from the events page of the Investors section of the Company’s website. Replay of the webcast will be available following the event.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | ||
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com | |
| Media Relations | ||
FR – Ulysse Communication Laurent Wormser + 33 (0)6 13 12 04 04 lwormser@ulysse-communication.com | Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com | |
Attachment
FAQ
What upcoming investor conferences will Nanobiotix (NBTX) attend in November 2024?
Where can I watch Nanobiotix (NBTX) conference presentations in November 2024?
Which Nanobiotix executives will present at the November 2024 healthcare conferences?
What time is Nanobiotix's presentation at the Jefferies London Healthcare Conference?
